- Home
- PHAT
as 03-31-2025 4:00pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 423.4M | IPO Year: | 2019 |
| Target Price: | $23.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.07 - $19.71 | Next Earning Date: | 03-06-2025 |
| Revenue: | $55,252,000 | Revenue Growth: | 8001.47% |
| Revenue Growth (this year): | 204.3% | Revenue Growth (next year): | 126.98% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parikh Asit | PHAT | Director | Mar 13 '25 | Buy | $4.42 | 10,000 | $44,200.00 | 85,500 | |
| Henderson Molly | PHAT | CFO and CBO | Jan 21 '25 | Sell | $6.59 | 6,583 | $43,370.78 | 93,546 | |
| Curran Terrie | PHAT | President and Chief Executive | Jan 21 '25 | Sell | $6.59 | 19,109 | $125,884.36 | 360,465 | |
| Nabulsi Azmi | PHAT | Chief Operating Officer | Jan 21 '25 | Sell | $6.59 | 7,886 | $51,956.91 | 233,390 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 hours ago
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
MT Newswires
12 days ago
Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating
Simply Wall St.
25 days ago
Phathom Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
25 days ago
Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...
Zacks
25 days ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
25 days ago
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GuruFocus.com
a month ago
Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result
GlobeNewswire
a month ago
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.